

REMARKS/ARGUMENTS

Claims 1-4, 6-9, 19, 21-27, 29, 32, 34-40, 42-46, 48-52 and 56-66 were examined. Applicant notes with appreciation that claims 19, 21-24, 32, and 34-37 are allowed. Claims 1-4, 6-9, 25-27, 29, 38-40, 42-46, 48-52 and 56-66 are rejected. Applicant cancels claims 1-4, 6-9, 25-27, 29, 38-40, 42-46, 48-52 and 56-66. Thus, only allowed claims remain. Hence, no prosecution issues remain.

Moreover, Applicant disagrees with the rejections of the current Office Action. Applicant reserves the right to file and prosecute claims as broad, or broader, than those remaining herein or cancelled. For example, Applicant reserves the right to file and prosecute the cancelled claims, or claims broader than the cancelled claims in a continuation application, a divisional application, or this application.

I. Claim Rejections Under 35 U.S.C §102

The Patent Office rejects claims 4 and 46 under 35 U.S.C. §102(e) as being anticipated by U.S. Patent Application Publication No. 2004/0005027 to Nafstadius (Nafstadius). The Patent Office rejects claims 56 and 60 under 35 U.S.C. §102(e) as being anticipated by U.S. Patent Application Publication No. 2003/0048868 to Bailey, et al. (Bailey). The Patent Office rejects claim 57 under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 6,301,325 to Besson et al. (Besson).

While, Applicant disagrees with the rejections above, all of the above noted claims have been cancelled.

II. Claim Rejections Under 35 U.S.C §103

The Patent Office rejects claims 1, 2, 25, 29, 38, 40, 42-44 and 65-66 under 35 U.S.C. §103(a) as being unpatentable over Chou et al. in view of Bailey et al. Claims 3 and 45 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chou et al. and Bailey et al. as applied to claims 1 and 43 above, and further in view of Weinberger et al. (US 5,764,723). Claims 61-64 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chou et al. and Bailey et al. as applied to claims 1 and 43 above, and further in view of U.S. Patent 5,138,647 to Nguyen, et al. (Nguyen). Claims 6, 8, 48, and 50 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nafstadius as applied to

claims 4 and 46 above, and further in view of Miller et al. (US 5,117,829). Claims 7 and 49 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nafstadius and Miller et al. as applied to claims 6 and 48 above, and further in view of Murphy et al. (US 5,901,199) and Jaffray et al. (US 2003/0007601). Claims 9 and 51 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nafstadius and Miller et al. as applied to claims 6 and 48 above, and further in view of Frohlich et al. (US 6,516,046). Claims 26, 27, and 39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Chou et al. and Bailey et al. as applied to claims 25 and 38 above, and further in view of Frohlich et al.. Claim 52 is rejected under 35 U.S.C. 103(a) as being unpatentable over Thornton (2002/0193677) in view of Ivan et al. (US 6,031,888). The Patent Office rejects claims 58 and 59 under 35 U.S.C. §103(a) as being unpatentable over U.S. Patent No. 6,535,574 to Collins et al. (Collins), in view of Toshiba “Clinical Performance: Delivering upon the Promise of Multi-slice CT through Proven Performance”.

While, Applicant disagrees with the rejections above, all of the above noted claims have been cancelled.

III. Allowable Subject Matter

Applicant notes with appreciation that claims 19, 21-24, 32 and 34-37 are allowed and the Reasons for Allowance therefore.

CONCLUSION

In view of the foregoing, it is believed that all claims now pending patentably define the subject invention over the prior art of record, and are in condition for allowance and such action is earnestly solicited at the earliest possible date. If the Examiner believes a telephone conference would be useful in moving the case forward, he is encouraged to contact the undersigned at (310) 207-3800.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2666 for any additional fees required under 37 C.F.R. §§ 1.16 or 1.17, particularly extension of time fees.

Respectfully submitted,




Angelo J. Gaz
Registration No. 45, 907

Dated: March 24, 2008


1279 Oakmead Parkway
Sunnyvale, California 94085-4040
Telephone (310) 207-3800
Facsimile (408) 720-8383

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence is being submitted to the United States Patent and Trademark Office electronically via EFS Web on the date shown below.



Robert Fiore



Date